Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance
Antimicrobial Agents and Chemotherapy · 10.01.2024 · 68 (1)
DOI: 10.1128/aac.00953-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 10.01.2024. Verfasst von Julie M Strizki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Merck Research Laboratories (MRL), Merck & Co., Inc. , Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Abstract (Originalsprache)
Molnupiravir, an oral prodrug of N-hydroxycytidine (NHC), previously demonstrated broad in vitro antiviral activity against multiple RNA viruses and has shown a high barrier to the development of resistance. Here, we present the antiviral activity of NHC against recent SARS-CoV-2 variants and the results of resistance selection studies to better understand the potential for viral resistance to NHC. NHC activity against SARS-CoV-2 variants omicron (BA.1, BA.1.1, BA.2, BA.4, BA.4.6, BA.5, BQ.1.1, XBB.1, and XBB.1.5), alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), lambda (C.37), and mu (B.1.621) was evaluated in Vero E6 cells using cytopathic effect assays. Resistance selection studies were performed by passaging SARS-CoV-2 (WA1) in the presence of NHC or a 3C-like protease inhibitor (MRK-A) in Vero E6 cells. Supernatants from cultures exhibiting a cytopathic effect score of ≥2 were re-passaged, and IC 50 values were estimated. Whole-genome deep sequencing was performed on viral RNA isolated at each passage. NHC demonstrated similar potency against all SARS-CoV-2 variants evaluated. No evidence of SARS-CoV-2 phenotypic or genotypic resistance to NHC was observed following 30 passages. A random pattern of nucleotide changes was observed in NHC cultures, consistent with the drug’s mechanism of action. In contrast, resistance was readily selected in all three MRK-A control cultures with the selection of a T21I substitution in the 3C-like protease. In conclusion, molnupiravir maintains antiviral activity across all major SARS-CoV-2 variants. Furthermore, no evidence of viral resistance to NHC was observed, supporting previous reports that NHC has a high barrier to developing resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck Research Laboratories (MRL), Merck & Co., Inc. , Rahway, New Jersey, USA.
- Aaron Diamond AIDS Research Center, Columbia University Medical Center , New York, New York, USA.
ORCID-Profile: Julie M Strizki
Förderung
- Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Zitieren
APA
Strizki, J. M., Gaspar, J. M., Howe, J. A., Hutchins, B., Mohri, H., Nair, M. S., Kinek, K. C., McKenna, P., Goh, S. L., & Murgolo, N. (2024). Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance. Antimicrobial Agents and Chemotherapy, 68(1). https://doi.org/10.1128/aac.00953-23
Vancouver
Strizki JM, Gaspar JM, Howe JA, Hutchins B, Mohri H, Nair MS, et al. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance. Antimicrobial Agents and Chemotherapy. 2024;68(1). doi:10.1128/aac.00953-23
BibTeX
@article{Strizki2024,
author = {Strizki, Julie M and Gaspar, John M and Howe, John A and Hutchins, Beth and Mohri, Hiroshi and Nair, Manoj S and Kinek, Keith C and McKenna, Philip and Goh, Shih Lin and Murgolo, Nicholas},
title = {Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {1},
doi = {10.1128/aac.00953-23}
}
EUVIMED